Full Press Release Details
AURORA CANNABIS INC.
Condensed Consolidated
Interim Financial Statements (Unaudited)
For the three months ended
September 30, 2022 and 2021 (in Canadian Dollars)
| Table of Contents | |
| Condensed Consolidated Interim Statements of Financial Position | 3 |
| Condensed Consolidated Interim Statements of Comprehensive Loss | 4 |
| Condensed Consolidated Interim Statements of Changes in Equity | 6 |
| Condensed Consolidated Interim Statements of Cash Flows | 8 |
| Notes to the Condensed Consolidated Interim Financial Statements |
| Note 1 | Nature of Operations | 9 | Note 15 | Loans and Borrowings | 21 |
| Note 2 | Significant Accounting Policies and Judgments | 9 | Note 16 | Lease Liabilities | 21 |
| Note 3 | Accounts Receivable | 11 | Note 17 | Share Capital | 22 |
| Note 4 | Government Grant | 11 | Note 18 | Share-Based Compensation | 23 |
| Note 5 | Marketable Securities and Derivatives | 12 | Note 19 | Loss per share | 25 |
| Note 6 | Investments in Associates and Joint Ventures | 12 | Note 20 | Other Gains (Losses | 26 |
| Note 7 | Biological Assets | 13 | Note 21 | Supplemental Cash Flow Information | 26 |
| Note 8 | Inventory | 15 | Note 22 | Commitments and Contingencies | 27 |
| Note 9 | Property, Plant and Equipment | 16 | Note 23 | Revenue | 28 |
| Note 10 | Assets and Liabilities Held for Sale | 17 | Note 24 | Segmented Information | 29 |
| Note 11 | Business Combinations | 17 | Note 25 | Fair Value of Financial Instruments | 30 |
| Note 12 | Non-controlling Interests | 19 | Note 26 | Financial Instruments Risk | 30 |
| Note 13 | Intangible Assets and Goodwill | 19 | Note 27 | Subsequent Events | 32 |
| Note 14 | Convertible Debentures | 20 |
| AURORA CANNABIS INC. |
| Condensed Consolidated Interim Statements of Financial Position |
| As at September 30, 2022 and June 30, 2022 Amounts reflected in thousands of Canadian dollars) |
| Notes | September 30, 2022 | June 30, 2022 | ||||||||||
| $ | $ | |||||||||||
| Assets | ||||||||||||
| Current | ||||||||||||
| Cash and cash equivalents | 369,278 | 437,807 | ||||||||||
| Restricted cash | 21 | 58,950 | 50,972 | |||||||||
| Accounts receivable | 3, 4, 26(a) | 45,841 | 46,995 | |||||||||
| Income taxes receivable | 100 | 57 | ||||||||||
| Marketable securities | 5(a) | 375 | 1,331 | |||||||||
| Biological assets | 7 | 19,735 | 23,827 | |||||||||
| Inventory | 8 | 126,507 | 116,098 | |||||||||
| Prepaids and other current assets | 5,395 | 6,539 | ||||||||||
| Assets held for sale | 10 | 55,645 | 61,495 | |||||||||
| 681,826 | 745,121 | |||||||||||
| Property, plant and equipment | 9 | 320,194 | 233,465 | |||||||||
| Derivatives | 5(b) | 25,611 | 26,283 | |||||||||
| Deposits | 2,860 | 3,134 | ||||||||||
| Loan receivable | 776 | 16 | ||||||||||
| Investments in associates and joint ventures | 6 | 1,237 | 1,207 | |||||||||
| Lease receivable | 4,391 | 4,434 | ||||||||||
| Intangible assets | 13 | 99,747 | 70,696 | |||||||||
| Goodwill | 13 | 18,750 | - | |||||||||
| Deferred tax assets | 11 | 14,535 | - | |||||||||
| Total assets | 1,169,927 | 1,084,356 | ||||||||||
| Liabilities | ||||||||||||
| Current | ||||||||||||
| Accounts payable and accrued liabilities | 26(b) | 96,664 | 69,874 | |||||||||
| Income taxes payable | 4,757 | 167 | ||||||||||
| Deferred revenue | 23 | 3,984 | 3,850 | |||||||||
| Convertible debentures | 14 | 29,826 | 26,854 | |||||||||
| Loans and borrowings | 15 | 3,342 | - | |||||||||
| Lease liabilities | 16 | 6,336 | 6,150 | |||||||||
| Provisions | 4,156 | 5,410 | ||||||||||
| Other current liabilities | 4 | 12,572 | 12,564 | |||||||||
| Liabilities held for sale | 10 | 5,996 | 5,988 | |||||||||
| 167,633 | 130,857 | |||||||||||
| Convertible debentures | 14 | 213,781 | 199,650 | |||||||||
| Loans and borrowings | 15 | 36,910 | - | |||||||||
| Lease liabilities | 16 | 35,372 | 36,837 | |||||||||
| Derivative liability | 14, 17(c) | 38,109 | 37,297 | |||||||||
| Contingent consideration payable | 11, 26(b) | 17,478 | 14,371 | |||||||||
| Other long-term liability | 11 | 48,751 | 128 | |||||||||
| Deferred tax liability | 11 | 17,396 | 2,862 | |||||||||
| Total liabilities | 575,430 | 422,002 | ||||||||||
| Shareholders' equity | ||||||||||||
| Share capital | 17 | 6,764,621 | 6,754,626 | |||||||||
| Reserves | 151,231 | 157,213 | ||||||||||
| Accumulated other comprehensive loss | (209,147 | ) | (211,721 | ) | ||||||||
| Deficit | (6,150,250 | ) | (6,038,275 | ) | ||||||||
| Total equity attributable to Aurora shareholders | 556,455 | 661,843 | ||||||||||
| Non-controlling interests | 12 | 38,042 | 511 | |||||||||
| Total equity | 594,497 | 662,354 | ||||||||||
| Total liabilities and equity | 1,169,927 | 1,084,356 | ||||||||||
| Nature of Operations (Note 1) | ||||||||||||
| Commitments and Contingencies (Note 22) | ||||||||||||
| Subsequent Events (Note 27) |
The accompanying notes are an integral part of these Condensed
Consolidated Interim Financial Statements.
| AURORA CANNABIS INC. |
| Condensed Consolidated Interim Statements of Comprehensive Loss |
| Three months ended September 30, 2022 and 2021 (Amounts reflected in thousands of Canadian dollars, except share and per share amounts) |
| Three months ended September 30, | ||||||||||||
| Notes | 2022 | 2021 | ||||||||||
| $ | $ | |||||||||||
| Revenue from sale of goods | 23 | 55,373 | 69,477 | |||||||||
| Revenue from provision of services | 23 | 362 | 449 | |||||||||
| Excise taxes | 23 | (6,472 | ) | (9,818 | ) | |||||||
| Net revenue | 49,263 | 60,108 | ||||||||||
| Cost of sales | 8 | 47,824 | 33,363 | |||||||||
| Gross profit before fair value adjustments | 1,439 | 26,745 | ||||||||||
| Changes in fair value of inventory sold | 8 | 24,263 | 12,642 | |||||||||
| Unrealized gain on changes in fair value of biological assets | 7 | (21,116 | ) | (11,345 | ) | |||||||
| Gross (loss) profit | (1,708 | ) | 25,448 | |||||||||
| Expense General and administration | 29,373 | 30,305 | ||||||||||
| Sales and marketing | 12,807 | 15,455 | ||||||||||
| Acquisition costs | 1,914 | 175 | ||||||||||
| Research and development | 1,603 | 3,671 | ||||||||||
| Depreciation and amortization | 9, 13 | 3,556 | 12,370 | |||||||||
| Share-based compensation | 18(a)(b)(c) | 2,863 | 2,847 | |||||||||
| 52,116 | 64,823 | |||||||||||
| Loss from operations | (53,824 | ) | (39,375 | ) | ||||||||
| Other (expense) income | ||||||||||||
| Legal settlement and contract termination fees | 22(a), (b)(i) | (639 | ) | (89 | ) | |||||||
| Interest and other income | 4,067 | 451 | ||||||||||
| Finance and other costs | 26(b) | (10,570 | ) | (15,340 | ) | |||||||
| Foreign exchange ("FX") (loss) gain | (1,182 | ) | 448 | |||||||||
| Other (losses) gain | 20 | (1,679 | ) | 43,146 | ||||||||
| Restructuring charges | (37 | ) | (1,333 | ) | ||||||||
| (10,040 | ) | 27,283 | ||||||||||
| Loss from operations before taxes | (63,864 | ) | (12,092 | ) | ||||||||
| Income tax (expense) recovery | ||||||||||||
| Current | (2,958 | ) | (173 | ) | ||||||||
| Deferred, net | 11 | 14,935 | 381 | |||||||||
| 11,977 | 208 | |||||||||||
| Net loss | (51,887 | ) | (11,884 | ) |
The accompanying notes are an integral part of these Condensed
Consolidated Interim Financial Statements.
| AURORA CANNABIS INC. |
| Condensed Consolidated Interim Statements of Comprehensive Loss |
| Three months ended September 30, 2022 and 2021 (Amounts reflected in thousands of Canadian dollars, except share and per share amounts) |
| (Continued) |
| Three months ended September 30, | ||||||||||||
| Notes | 2022 | 2021 | ||||||||||
| $ | $ | |||||||||||
| Other comprehensive (loss) income ("OCI") that will not be reclassified to net loss | ||||||||||||
| Unrealized gain on marketable securities | 5(a) | (753 | ) | (916 | ) | |||||||
| (753 | ) | (916 | ) | |||||||||
| Other comprehensive (loss) income that may be reclassified to net loss | ||||||||||||
| Share of loss from investment in associates | 6 | - | (2 | ) | ||||||||
| Foreign currency translation loss (gain) | 3,327 | (2,308 | ) | |||||||||
| 3,327 | (2,310 | ) | ||||||||||
| Total other comprehensive loss (gain) | 2,574 | (3,226 | ) | |||||||||
| Comprehensive loss | (49,313 | ) | (15,110 | ) | ||||||||
| Net loss attributable to: | ||||||||||||
| Aurora Cannabis Inc. | (51,604 | ) | (11,884 | ) | ||||||||
| Non-controlling interests | 12 | (283 | ) | - | ||||||||
| Comprehensive loss attributable to: | ||||||||||||
| Aurora Cannabis Inc. | (49,030 | ) | (15,110 | ) | ||||||||
| Non-controlling interests | (283 | ) | - | |||||||||
| Loss per share - basic and diluted | ||||||||||||
| Total operations | 19 | ($ | 0.17 | ) | ($ | 0.06 | ) |
The accompanying notes are an integral part of these Condensed
Consolidated Interim Financial Statements.
| AURORA CANNABIS INC. |
| Condensed Consolidated Interim Statements of Changes in Equity |
| Three months ended September 30, 2022 ( Amounts reflected in thousands of Canadian dollars, except share amounts) |
| Share Capital | Reserves | AOCI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Note | Common Shares | Amount | Share-Based Compensation | Compensation Options/Warrants/ Shares to be Issued | Convertible Notes | Change in Ownership Interest | Obligation to Issue Shares | Total Reserves | Fair Value | Deferred Tax | Associate OCI Pick-up | Foreign Currency Translation | Total AOCI | Deficit | Non-Controlling Interests | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| # | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2022 | 297,772,238 | 6,754,626 | 206,244 | 37,350 | 419 | (86,800 | ) | - | 157,213 | (213,394 | ) | 18,919 | 208 | (17,454 | ) | (211,721 | ) | (6,038,275 | ) | 511 | 662,354 | |||||||||||||||||||||||||||||||||||||||||||||||
| Shares issued/issuable for business combinations | 11, 17(b) | 2,614,995 | 9,683 | - | (9,683 | ) | - | - | - | (9,683 | ) | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares issued through equity financing | 17(b) | - | - | - | - | - | - | 1,448 | 1,448 | - | - | - | - | - | - | - | 1,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity financing transaction costs | - | (119 | ) | - | - | - | - | - | - | - | - | - | - | - | - | - | (119 | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Deferred tax on transaction costs | - | (179 | ) | - | - | - | - | - | - | - | - | - | - | - | - | - | (179 | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Exercise of RSUs, PSUs and DSUs | 18(b) | 50,200 | 610 | (610 | ) | - | - | - | - | (610 | ) | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | 18 | - | - | 2,863 | - | - | - | - | 2,863 | - | - | - | - | - | - | - | 2,863 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| NCI contribution | 12 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25,891 | 25,891 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Recognition of put option liability | 11 | - | - | - | - | - | - | - | - | - | - | - | - | - | (48,448 | ) | - | (48,448 | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Change in ownership interests in net assets | 12 | - | - | - | - | - | - | - | - | - | - | - | - | - | (11,923 | ) | 11,923 | - | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Comprehensive loss for the period | - | - | - | - | - | - | - | - | (753 | ) | - | - | 3,327 | 2,574 | (51,604 | ) | (283 | ) | (49,313 | ) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, September 30, 2022 | 300,437,433 | 6,764,621 | 208,497 | 27,667 | 419 | (86,800 | ) | 1,448 | 151,231 | (214,147 | ) | 18,919 | 208 | (14,127 | ) | (209,147 | ) | (6,150,250 | ) | 38,042 | 594,497 |
The accompanying notes are an integral part of these Condensed
Consolidated Interim Financial Statements.
| AURORA CANNABIS INC. |
| Condensed Consolidated Interim Statements of Changes in Equity |
| Three months ended September 30, 2022 ( Amounts reflected in thousands of Canadian dollars, except share amounts) |
| Share Capital | Reserves | AOCI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Note | Common Shares | Amount | Share-Based Compensation | Compensation Options/ Warrants | Convertible Notes | Change in Ownership Interest | Total Reserves | Fair Value | Deferred Tax | Associate OCI Pick-up | Foreign Currency Translation | Total AOCI | Deficit | Non-Controlling Interests | Total | |||||||||||||||||||||||||||||||||||||||||||||||||
| # | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2021 | 198,068,923 | 6,424,296 | 200,214 | 27,667 | 419 | (86,800 | ) | 141,500 | (211,327 | ) | 18,919 | 210 | (14,813 | ) | (207,011 | ) | (4,321,085 | ) | - | 2,037,700 | ||||||||||||||||||||||||||||||||||||||||||||
| Equity financing transaction costs | - | (84 | ) | - | - | - | - | - | - | - | - | - | - | - | - | (84 | ) | |||||||||||||||||||||||||||||||||||||||||||||||
| Deferred tax on transaction costs | - | (381 | ) | - | - | - | - | - | - | - | - | - | - | - | - | (381 | ) | |||||||||||||||||||||||||||||||||||||||||||||||
| Exercise of RSUs and DSUs | 18(b) | 11,675 | 342 | (342 | ) | - | - | - | (342 | ) | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | 18 | - | - | 2,847 | - | - | - | 2,847 | - | - | - | - | - | - | - | 2,847 | ||||||||||||||||||||||||||||||||||||||||||||||||
| NCI Contribution | 12 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||
| Shares issued from treasury | 44,390 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
| Comprehensive income (loss) for the period | - | - | - | - | - | - | - | (916 | ) | - | (2 | ) | (2,308 | ) | (3,226 | ) | (11,884 | ) | - | (15,110 | ) | |||||||||||||||||||||||||||||||||||||||||||
| Balance, September 30, 2021 | 198,124,988 | 6,424,173 | 202,719 | 27,667 | 419 | (86,800 | ) | 144,005 | (212,243 | ) | 18,919 | 208 | (17,121 | ) | (210,237 | ) | (4,332,969 | ) | - | 2,024,972 |
The accompanying notes are an integral part of these Condensed
Consolidated Interim Financial Statements.
| AURORA CANNABIS INC. |
| Condensed Consolidated Interim Statements of Cash Flows |
| Three months ended September 30, 2022 and 2021 (Amounts reflected in thousands of Canadian dollars) |
| Three months ended September 30, 2021 | ||||||||||||
| Notes | 2022 | 2021 | ||||||||||
| $ | $ | |||||||||||
| Operating activities | ||||||||||||
| Net loss from continuing operations | (51,887 | ) | (11,884 | ) | ||||||||
| Adjustments for non-cash items: | ||||||||||||
| Unrealized gain on changes in fair value of biological assets | 7 | (21,116 | ) | (11,345 | ) | |||||||
| Changes in fair value included in inventory sold | 8 | 24,263 | 12,642 | |||||||||
| Depreciation of property, plant and equipment | 9 | 9,778 | 16,170 | |||||||||
| Amortization of intangible assets | 13 | 181 | 8,417 | |||||||||
| Share-based compensation | 2,863 | 2,847 | ||||||||||
| Accrued interest and accretion expense | 14 | 2,898 | 2,525 | |||||||||
| Interest and other expense (income) | 2 | (337 | ) | |||||||||
| Deferred tax recovery | (14,935 | ) | (381 | ) | ||||||||
| Other losses (gains) | 20 | 1,679 | (28,734 | ) | ||||||||
| Foreign exchange (gain) loss | 6,110 | (519 | ) | |||||||||
| Restructuring charges | 37 | 813 | ||||||||||
| Changes in non-cash working capital | 21 | 8,989 | (12,886 | ) | ||||||||
| Net cash used in operating activities | (31,138 | ) | (22,672 | ) | ||||||||
| Investing activities | ||||||||||||
| Investment in derivatives | 203 | - | ||||||||||
| Loan receivable | (760 | ) | (2,849 | ) | ||||||||
| Purchase of property, plant and equipment and intangible assets | (5,555 | ) | (4,104 | ) | ||||||||
| Disposal of property, plant and equipment | 5,573 | 7,157 | ||||||||||
| Acquisition of businesses, net of cash acquired | 11 | (38,790 | ) | - | ||||||||
| Deposits (paid) received | (2,602 | ) | 155 | |||||||||
| Net cash provided by (used in) investing activities | (41,931 | ) | 359 | |||||||||
| Financing activities | ||||||||||||
| Proceeds from long term loans | 842 | - | ||||||||||
| Repayment of short-term loans | (701 | ) | - | |||||||||
| Payments of principal portion of lease liabilities | 16 | (1,678 | ) | (1,551 | ) | |||||||
| Restricted cash | (7,978 | ) | (32,116 | ) | ||||||||
| Shares issued for cash, net of share issue costs | (119 | ) | (84 | ) | ||||||||
| Net cash used in financing activities | (9,634 | ) | (33,751 | ) | ||||||||
| Effect of foreign exchange on cash and cash equivalents | 14,174 | 7,398 | ||||||||||
| Decrease in cash and cash equivalents | (68,529 | ) | (48,666 | ) | ||||||||
| Cash and cash equivalents, beginning of period | 437,807 | 421,457 | ||||||||||
| Cash and cash equivalents, end of period | 369,278 | 372,791 | ||||||||||
| Supplemental cash flow information (Note 21) | ||||||||||||
| The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements. |
| AURORA CANNABIS INC. | |
| Notes to the Condensed Consolidated Interim Financial Statements | |
| Three months ended September 30, 2022 and 2021 (Amounts reflected in thousands of Canadian dollars, except share and per share amounts) |
Aurora Cannabis Inc. (the "Company"
or "Aurora") was incorporated under the Business Corporations Act (British Columbia) on December 21, 2006 as Milk Capital
Corp. Effective October 2, 2014, the Company changed its name to Aurora Cannabis Inc. The Company's shares are listed on the Nasdaq
Global Select Market ("Nasdaq") and the Toronto Stock Exchange ("TSX") under the trading symbol "ACB",
and on the Frankfurt Stock Exchange ("FSE") under the trading symbol "21P".
The Company's head office
and principal address is 500 - 10355 Jasper Avenue, Edmonton, Alberta, Canada, T5J 1Y6. The Company's registered and records office
address is Suite 1700, 666 Burrard Street , Vancouver, British Columbia, V6C 2X8.
The Company's principal strategic
business lines are focused on the production, distribution and sale of cannabis related products in Canada and internationally. Aurora
currently conducts the following key business activities in the jurisdictions listed below:
On August 25, 2022, the Company
acquired a 50.1% controlling interest in Bevo Agtech Inc. ("Bevo"), the sole parent of Bevo Farms Ltd. in order to support
the Company's principal cannabis operations. Bevo is one of the largest suppliers of propagated vegetables and ornamental plants
Accounting Policies and Judgments
The condensed consolidated interim
financial statements of the Company have been prepared in accordance with International Financial Reporting Standards ("IFRS")
and International Accounting Standards 34, "Interim Financial Reporting" ("IAS 34") as issued by the International
Accounting Standards Board ("IASB"), and interpretations of the IFRS Interpretations Committee ("IFRIC"). Unless
otherwise noted, all amounts are presented in thousands of Canadian dollars, except share and per share data.
The Company has reclassified certain comparative balances to conform
with the current period's presentation.
The condensed consolidated interim
financial statements are presented in Canadian dollars and are prepared in accordance with the same accounting policies, critical estimates
and methods described in the Company's annual consolidated financial statements, except for the adoption of new accounting policies
(Note 2(c) and (d)). Given that certain information and footnote disclosures, which are included in the annual audited consolidated financial
statements, have been condensed or excluded in accordance with IAS 34, these condensed consolidated interim financial statements should
be read in conjunction with our annual audited consolidated financial statements as at and for the year ended June 30, 2022, including
the accompanying notes thereto.
The consolidated financial statements
include the financial results of the Company and its subsidiaries. Subsidiaries include entities which are wholly-owned as well as entities
over which Aurora has the authority or ability to exert power over the investee's financial and/or operating decisions (i.e. control),
which in turn may affect the Company's exposure or rights to the variable returns from the investee. The consolidated financial
statements include the operating results of acquired or disposed entities from the date control is obtained or the date control is lost,
respectively. All intercompany balances and transactions are eliminated upon consolidation.
The Company's principal subsidiaries during the three months
ended September 30, 2022 are as follows:
| AURORA CANNABIS INC. | |
| Notes to the Condensed Consolidated Interim Financial Statements | |
| Three months ended September 30, 2022 and 2021 (Amounts reflected in thousands of Canadian dollars, except share and per share amounts) |
| Major subsidiaries | Percentage Ownership | Functional Currency |
| 1769474 Alberta Ltd. ("1769474") | 100% | Canadian Dollar |
| 2105657 Alberta Inc. ("2105657") | 100% | Canadian Dollar |
| Aurora Cannabis Enterprises Inc. ("ACE") | 100% | Canadian Dollar |
| Aurora Deutschland GmbH ("Aurora Deutschland") | 100% | European Euro |
| Aurora Nordic Cannabis A/S ("Aurora Nordic") | 100% | Danish Krone |
| Reliva, LLC ("Reliva") | 100% | United States Dollar |
| TerraFarma Inc. | 100% | Canadian Dollar |
| Whistler Medical Marijuana Corporation ("Whistler") | 100% | Canadian Dollar |
| Bevo Agtech Inc. | 50.1% | Canadian Dollar |
| CannaHealth Therapeutics Inc. | 100% | Canadian Dollar |
| ACB Captive Insurance Company Inc. | 100% | Canadian Dollar |
All shareholdings are of ordinary
shares or other equity. Other subsidiaries, while included in the consolidated financial statements, are not material and have not been
reflected in the table above.
Put Option Liability
The Company has entered into a
put option with certain non-controlling interest shareholders of Bevo such that the Company is required to purchase their shareholding
under certain conditions as of the exercise date. When accounting for options related to non-controlling interests, the Company applies
IFRS 10, Consolidated Financial Statements, and the terms of the contracts are analyzed to assess whether they provide the Company
or the non-controlling interest with access to the risks and rewards associated with the actual ownership of the shares. The Company has
elected the present-access method of accounting for non-controlling interests. As a result, the Company has recognized a financial liability
at the present value of the amount payable on exercise of the put option. Remeasurement adjustments are recorded in defict.
of New Accounting Pronouncements
Amendments to IAS 41: Agriculture
As part of its 2018-2020 annual
improvements to IFRS standards process, the IASB issued amendments to IAS 41. The amendment removes the requirement for entities to exclude
taxation cash flow when measuring the fair value of a biological asset using a present value technique. This will ensure consistency with
the requirements in IFRS 13. The amendment is effective for annual reporting periods beginning on or after January 1, 2022. The Company
adopted the Amendments to IFRS 41 effective July 1, 2022 which did not have a material impact to the Company's consolidated financial
Amendments to IFRS 9: Financial Instruments
As part of its 2018-2020 annual
improvements to IFRS standards process, the IASB issued amendments to IFRS 9. The amendment clarifies the fees that an entity includes
when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial
liability. These fees include only those paid or received between the borrower and the lender, including fees paid or received by either
the borrower or lender on the other's behalf. An entity applies the amendment to financial liabilities that are modified or exchanged
on or after the beginning of the annual reporting period in which the entity first applies the amendment. The amendment is effective for
annual reporting periods beginning on or after January 1, 2022 with earlier adoption permitted. The Company adopted the Amendments to
IFRS 9 effective July 1, 2022 which did not have a material impact to the Company's consolidated financial statements.
Amendments to IAS 37: Onerous Contracts
and the Cost of Fulfilling a Contract
The amendment specifies that the
cost of fulfilling' a contract comprises the costs that relate directly to the contract'. Costs that relate